CA Patent

CA3165238A1 — Kras mutant protein inhibitors

Assigned to Jacobio Pharmaceuticals Co Ltd · Expires 2021-06-24 · 5y expired

What this patent protects

The invention relates to a KRAS mutant protein inhibitor shown as formula (I), a composition containing the inhibitor and the use thereof.

USPTO Abstract

The invention relates to a KRAS mutant protein inhibitor shown as formula (I), a composition containing the inhibitor and the use thereof.

Drugs covered by this patent

Patent Metadata

Patent number
CA3165238A1
Jurisdiction
CA
Classification
—
Expires
2021-06-24
Drug substance claim
No
Drug product claim
No
Assignee
Jacobio Pharmaceuticals Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.